| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation: 17/05/1998, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 16:02

Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation: 17/05/1998, Revision: 20, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation: 17/05/1998, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 31, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 15:40

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 31, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 15:16

Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 2, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 15:05

Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 6, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 14:46

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised

SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 15:30 (CET)

Submitted by Anonymous (not verified) on 29 May 2026 - 14:01

SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 15:30 (CET)

Read more about SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 15:30 (CET)

Human medicines European public assessment report (EPAR): Teriflunomide Viatris (previously Teriflunomide Mylan), teriflunomide, Date of authorisation: 09/11/2022, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 14:00

Human medicines European public assessment report (EPAR): Teriflunomide Viatris (previously Teriflunomide Mylan), teriflunomide, Date of authorisation: 09/11/2022, Revision: 8, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Teriflunomide Viatris (previously Teriflunomide Mylan), teriflunomide, Date of authorisation: 09/11/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 13:55

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 29 May 2026 - 13:52

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation: 17/05/1998, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised

SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 15:30 (CET)

Human medicines European public assessment report (EPAR): Teriflunomide Viatris (previously Teriflunomide Mylan), teriflunomide, Date of authorisation: 09/11/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters